nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.125	0.195	CbGbCtD
Meloxicam—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0872	0.136	CbGbCtD
Meloxicam—CYP2C8—Progesterone—uterine cancer	0.0828	0.129	CbGbCtD
Meloxicam—PTGS2—Etoposide—uterine cancer	0.076	0.119	CbGbCtD
Meloxicam—PTGS1—Etoposide—uterine cancer	0.0642	0.1	CbGbCtD
Meloxicam—CYP2C9—Progesterone—uterine cancer	0.0578	0.0903	CbGbCtD
Meloxicam—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0507	0.0793	CbGbCtD
Meloxicam—CYP2C8—Etoposide—uterine cancer	0.0371	0.0579	CbGbCtD
Meloxicam—CYP3A4—Progesterone—uterine cancer	0.0336	0.0525	CbGbCtD
Meloxicam—CYP3A4—Etoposide—uterine cancer	0.015	0.0235	CbGbCtD
Meloxicam—CYP3A4—Doxorubicin—uterine cancer	0.0103	0.016	CbGbCtD
Meloxicam—PTGS1—oviduct—uterine cancer	0.00406	0.0624	CbGeAlD
Meloxicam—PGD—myometrium—uterine cancer	0.00311	0.0476	CbGeAlD
Meloxicam—PTGS1—artery—uterine cancer	0.00269	0.0413	CbGeAlD
Meloxicam—PTGS2—artery—uterine cancer	0.00257	0.0395	CbGeAlD
Meloxicam—PGD—uterine cervix—uterine cancer	0.00242	0.0371	CbGeAlD
Meloxicam—PGD—smooth muscle tissue—uterine cancer	0.00235	0.036	CbGeAlD
Meloxicam—PGD—decidua—uterine cancer	0.0023	0.0353	CbGeAlD
Meloxicam—PGD—renal system—uterine cancer	0.00226	0.0347	CbGeAlD
Meloxicam—PGD—endometrium—uterine cancer	0.00219	0.0335	CbGeAlD
Meloxicam—PGD—mammalian vulva—uterine cancer	0.00211	0.0324	CbGeAlD
Meloxicam—PGD—uterus—uterine cancer	0.00201	0.0309	CbGeAlD
Meloxicam—PGD—female reproductive system—uterine cancer	0.00181	0.0278	CbGeAlD
Meloxicam—PGD—female gonad—uterine cancer	0.00165	0.0253	CbGeAlD
Meloxicam—PGD—vagina—uterine cancer	0.00164	0.0251	CbGeAlD
Meloxicam—ABCC4—renal system—uterine cancer	0.00161	0.0247	CbGeAlD
Meloxicam—ABCC4—uterus—uterine cancer	0.00143	0.022	CbGeAlD
Meloxicam—ABCC4—female reproductive system—uterine cancer	0.00129	0.0198	CbGeAlD
Meloxicam—PTGS2—myometrium—uterine cancer	0.00124	0.0191	CbGeAlD
Meloxicam—ABCC4—female gonad—uterine cancer	0.00117	0.018	CbGeAlD
Meloxicam—CYP2C8—renal system—uterine cancer	0.00117	0.0179	CbGeAlD
Meloxicam—CYP2C8—endometrium—uterine cancer	0.00113	0.0173	CbGeAlD
Meloxicam—PGD—lymph node—uterine cancer	0.00106	0.0163	CbGeAlD
Meloxicam—PTGS1—epithelium—uterine cancer	0.00102	0.0157	CbGeAlD
Meloxicam—PTGS1—uterine cervix—uterine cancer	0.00101	0.0155	CbGeAlD
Meloxicam—PTGS1—smooth muscle tissue—uterine cancer	0.000984	0.0151	CbGeAlD
Meloxicam—PTGS2—epithelium—uterine cancer	0.000976	0.015	CbGeAlD
Meloxicam—PTGS2—uterine cervix—uterine cancer	0.000967	0.0148	CbGeAlD
Meloxicam—PTGS1—renal system—uterine cancer	0.000947	0.0145	CbGeAlD
Meloxicam—PTGS2—smooth muscle tissue—uterine cancer	0.00094	0.0144	CbGeAlD
Meloxicam—CYP2C8—female reproductive system—uterine cancer	0.000935	0.0143	CbGeAlD
Meloxicam—PTGS1—endometrium—uterine cancer	0.000915	0.014	CbGeAlD
Meloxicam—PTGS2—renal system—uterine cancer	0.000905	0.0139	CbGeAlD
Meloxicam—PTGS1—mammalian vulva—uterine cancer	0.000885	0.0136	CbGeAlD
Meloxicam—PTGS2—endometrium—uterine cancer	0.000875	0.0134	CbGeAlD
Meloxicam—CYP2C8—vagina—uterine cancer	0.000846	0.013	CbGeAlD
Meloxicam—PTGS1—uterus—uterine cancer	0.000844	0.0129	CbGeAlD
Meloxicam—CYP2C9—female reproductive system—uterine cancer	0.000831	0.0127	CbGeAlD
Meloxicam—PTGS2—uterus—uterine cancer	0.000806	0.0124	CbGeAlD
Meloxicam—CYP3A4—renal system—uterine cancer	0.000791	0.0121	CbGeAlD
Meloxicam—PTGS1—female reproductive system—uterine cancer	0.000758	0.0116	CbGeAlD
Meloxicam—ABCC4—lymph node—uterine cancer	0.000753	0.0116	CbGeAlD
Meloxicam—PTGS2—female reproductive system—uterine cancer	0.000725	0.0111	CbGeAlD
Meloxicam—PTGS1—female gonad—uterine cancer	0.00069	0.0106	CbGeAlD
Meloxicam—PTGS1—vagina—uterine cancer	0.000686	0.0105	CbGeAlD
Meloxicam—PTGS2—female gonad—uterine cancer	0.00066	0.0101	CbGeAlD
Meloxicam—PTGS2—vagina—uterine cancer	0.000656	0.0101	CbGeAlD
Meloxicam—CYP3A4—female reproductive system—uterine cancer	0.000633	0.00972	CbGeAlD
Meloxicam—PTGS1—lymph node—uterine cancer	0.000444	0.00681	CbGeAlD
Meloxicam—PTGS2—lymph node—uterine cancer	0.000424	0.00651	CbGeAlD
Meloxicam—Pancreatitis—Epirubicin—uterine cancer	0.000213	0.000793	CcSEcCtD
Meloxicam—Abdominal pain upper—Doxorubicin—uterine cancer	0.000213	0.000791	CcSEcCtD
Meloxicam—Angina pectoris—Epirubicin—uterine cancer	0.000212	0.000788	CcSEcCtD
Meloxicam—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.00021	0.00078	CcSEcCtD
Meloxicam—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.00021	0.00078	CcSEcCtD
Meloxicam—Bronchitis—Epirubicin—uterine cancer	0.000209	0.000778	CcSEcCtD
Meloxicam—Diarrhoea—Dactinomycin—uterine cancer	0.000209	0.000776	CcSEcCtD
Meloxicam—Nasopharyngitis—Doxorubicin—uterine cancer	0.000208	0.000775	CcSEcCtD
Meloxicam—Pancytopenia—Epirubicin—uterine cancer	0.000207	0.000769	CcSEcCtD
Meloxicam—Hypotension—Etoposide—uterine cancer	0.000206	0.000767	CcSEcCtD
Meloxicam—Gastritis—Doxorubicin—uterine cancer	0.000206	0.000767	CcSEcCtD
Meloxicam—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000205	0.000764	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000202	0.000752	CcSEcCtD
Meloxicam—Influenza—Doxorubicin—uterine cancer	0.000201	0.000749	CcSEcCtD
Meloxicam—Asthma—Doxorubicin—uterine cancer	0.000201	0.000749	CcSEcCtD
Meloxicam—Pollakiuria—Epirubicin—uterine cancer	0.000201	0.000748	CcSEcCtD
Meloxicam—Photosensitivity reaction—Epirubicin—uterine cancer	0.000199	0.000739	CcSEcCtD
Meloxicam—Paraesthesia—Etoposide—uterine cancer	0.000198	0.000737	CcSEcCtD
Meloxicam—Weight increased—Epirubicin—uterine cancer	0.000198	0.000736	CcSEcCtD
Meloxicam—Pancreatitis—Doxorubicin—uterine cancer	0.000197	0.000734	CcSEcCtD
Meloxicam—Weight decreased—Epirubicin—uterine cancer	0.000197	0.000732	CcSEcCtD
Meloxicam—Dyspnoea—Etoposide—uterine cancer	0.000197	0.000732	CcSEcCtD
Meloxicam—Somnolence—Etoposide—uterine cancer	0.000196	0.00073	CcSEcCtD
Meloxicam—Angina pectoris—Doxorubicin—uterine cancer	0.000196	0.000729	CcSEcCtD
Meloxicam—Infestation NOS—Epirubicin—uterine cancer	0.000194	0.000722	CcSEcCtD
Meloxicam—Infestation—Epirubicin—uterine cancer	0.000194	0.000722	CcSEcCtD
Meloxicam—Drowsiness—Epirubicin—uterine cancer	0.000194	0.000722	CcSEcCtD
Meloxicam—Vomiting—Dactinomycin—uterine cancer	0.000194	0.000721	CcSEcCtD
Meloxicam—Bronchitis—Doxorubicin—uterine cancer	0.000194	0.00072	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000192	0.000715	CcSEcCtD
Meloxicam—Rash—Dactinomycin—uterine cancer	0.000192	0.000715	CcSEcCtD
Meloxicam—Decreased appetite—Etoposide—uterine cancer	0.000192	0.000714	CcSEcCtD
Meloxicam—Pancytopenia—Doxorubicin—uterine cancer	0.000191	0.000711	CcSEcCtD
Meloxicam—Renal failure—Epirubicin—uterine cancer	0.000191	0.000709	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Etoposide—uterine cancer	0.00019	0.000709	CcSEcCtD
Meloxicam—Fatigue—Etoposide—uterine cancer	0.00019	0.000708	CcSEcCtD
Meloxicam—Jaundice—Epirubicin—uterine cancer	0.000189	0.000703	CcSEcCtD
Meloxicam—Stomatitis—Epirubicin—uterine cancer	0.000189	0.000703	CcSEcCtD
Meloxicam—Pain—Etoposide—uterine cancer	0.000189	0.000702	CcSEcCtD
Meloxicam—Constipation—Etoposide—uterine cancer	0.000189	0.000702	CcSEcCtD
Meloxicam—Urinary tract infection—Epirubicin—uterine cancer	0.000188	0.000701	CcSEcCtD
Meloxicam—Conjunctivitis—Epirubicin—uterine cancer	0.000188	0.000701	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000187	0.000696	CcSEcCtD
Meloxicam—Sweating—Epirubicin—uterine cancer	0.000186	0.000692	CcSEcCtD
Meloxicam—Pollakiuria—Doxorubicin—uterine cancer	0.000186	0.000692	CcSEcCtD
Meloxicam—Haematuria—Epirubicin—uterine cancer	0.000185	0.000688	CcSEcCtD
Meloxicam—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000184	0.000683	CcSEcCtD
Meloxicam—Hepatobiliary disease—Epirubicin—uterine cancer	0.000183	0.000682	CcSEcCtD
Meloxicam—Weight increased—Doxorubicin—uterine cancer	0.000183	0.000681	CcSEcCtD
Meloxicam—Weight decreased—Doxorubicin—uterine cancer	0.000182	0.000677	CcSEcCtD
Meloxicam—Sinusitis—Epirubicin—uterine cancer	0.000182	0.000677	CcSEcCtD
Meloxicam—Feeling abnormal—Etoposide—uterine cancer	0.000182	0.000677	CcSEcCtD
Meloxicam—Nausea—Dactinomycin—uterine cancer	0.000181	0.000674	CcSEcCtD
Meloxicam—Agranulocytosis—Epirubicin—uterine cancer	0.000181	0.000673	CcSEcCtD
Meloxicam—Gastrointestinal pain—Etoposide—uterine cancer	0.00018	0.000671	CcSEcCtD
Meloxicam—Infestation—Doxorubicin—uterine cancer	0.000179	0.000668	CcSEcCtD
Meloxicam—Infestation NOS—Doxorubicin—uterine cancer	0.000179	0.000668	CcSEcCtD
Meloxicam—Drowsiness—Doxorubicin—uterine cancer	0.000179	0.000668	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000178	0.000662	CcSEcCtD
Meloxicam—Renal failure—Doxorubicin—uterine cancer	0.000176	0.000656	CcSEcCtD
Meloxicam—Urticaria—Etoposide—uterine cancer	0.000175	0.000652	CcSEcCtD
Meloxicam—Haemoglobin—Epirubicin—uterine cancer	0.000175	0.000651	CcSEcCtD
Meloxicam—Stomatitis—Doxorubicin—uterine cancer	0.000175	0.000651	CcSEcCtD
Meloxicam—Jaundice—Doxorubicin—uterine cancer	0.000175	0.000651	CcSEcCtD
Meloxicam—Rhinitis—Epirubicin—uterine cancer	0.000175	0.000649	CcSEcCtD
Meloxicam—Body temperature increased—Etoposide—uterine cancer	0.000174	0.000649	CcSEcCtD
Meloxicam—Abdominal pain—Etoposide—uterine cancer	0.000174	0.000649	CcSEcCtD
Meloxicam—Conjunctivitis—Doxorubicin—uterine cancer	0.000174	0.000649	CcSEcCtD
Meloxicam—Urinary tract infection—Doxorubicin—uterine cancer	0.000174	0.000649	CcSEcCtD
Meloxicam—Hepatitis—Epirubicin—uterine cancer	0.000174	0.000648	CcSEcCtD
Meloxicam—Haemorrhage—Epirubicin—uterine cancer	0.000174	0.000648	CcSEcCtD
Meloxicam—Pharyngitis—Epirubicin—uterine cancer	0.000173	0.000643	CcSEcCtD
Meloxicam—Sweating—Doxorubicin—uterine cancer	0.000172	0.00064	CcSEcCtD
Meloxicam—Urinary tract disorder—Epirubicin—uterine cancer	0.000172	0.00064	CcSEcCtD
Meloxicam—Oedema peripheral—Epirubicin—uterine cancer	0.000171	0.000638	CcSEcCtD
Meloxicam—Haematuria—Doxorubicin—uterine cancer	0.000171	0.000637	CcSEcCtD
Meloxicam—Connective tissue disorder—Epirubicin—uterine cancer	0.000171	0.000637	CcSEcCtD
Meloxicam—Urethral disorder—Epirubicin—uterine cancer	0.000171	0.000635	CcSEcCtD
Meloxicam—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00017	0.000631	CcSEcCtD
Meloxicam—Sinusitis—Doxorubicin—uterine cancer	0.000168	0.000626	CcSEcCtD
Meloxicam—Visual impairment—Epirubicin—uterine cancer	0.000168	0.000624	CcSEcCtD
Meloxicam—Agranulocytosis—Doxorubicin—uterine cancer	0.000167	0.000623	CcSEcCtD
Meloxicam—Erythema multiforme—Epirubicin—uterine cancer	0.000165	0.000612	CcSEcCtD
Meloxicam—Eye disorder—Epirubicin—uterine cancer	0.000163	0.000605	CcSEcCtD
Meloxicam—Hypersensitivity—Etoposide—uterine cancer	0.000163	0.000605	CcSEcCtD
Meloxicam—Tinnitus—Epirubicin—uterine cancer	0.000162	0.000604	CcSEcCtD
Meloxicam—Haemoglobin—Doxorubicin—uterine cancer	0.000162	0.000602	CcSEcCtD
Meloxicam—Flushing—Epirubicin—uterine cancer	0.000162	0.000601	CcSEcCtD
Meloxicam—Cardiac disorder—Epirubicin—uterine cancer	0.000162	0.000601	CcSEcCtD
Meloxicam—Rhinitis—Doxorubicin—uterine cancer	0.000161	0.000601	CcSEcCtD
Meloxicam—Hepatitis—Doxorubicin—uterine cancer	0.000161	0.000599	CcSEcCtD
Meloxicam—Haemorrhage—Doxorubicin—uterine cancer	0.000161	0.000599	CcSEcCtD
Meloxicam—Pharyngitis—Doxorubicin—uterine cancer	0.00016	0.000595	CcSEcCtD
Meloxicam—Urinary tract disorder—Doxorubicin—uterine cancer	0.000159	0.000592	CcSEcCtD
Meloxicam—Oedema peripheral—Doxorubicin—uterine cancer	0.000159	0.00059	CcSEcCtD
Meloxicam—Asthenia—Etoposide—uterine cancer	0.000158	0.000589	CcSEcCtD
Meloxicam—Connective tissue disorder—Doxorubicin—uterine cancer	0.000158	0.000589	CcSEcCtD
Meloxicam—Angiopathy—Epirubicin—uterine cancer	0.000158	0.000588	CcSEcCtD
Meloxicam—Urethral disorder—Doxorubicin—uterine cancer	0.000158	0.000588	CcSEcCtD
Meloxicam—Immune system disorder—Epirubicin—uterine cancer	0.000157	0.000585	CcSEcCtD
Meloxicam—Mediastinal disorder—Epirubicin—uterine cancer	0.000157	0.000584	CcSEcCtD
Meloxicam—Pruritus—Etoposide—uterine cancer	0.000156	0.000581	CcSEcCtD
Meloxicam—Arrhythmia—Epirubicin—uterine cancer	0.000156	0.000579	CcSEcCtD
Meloxicam—Visual impairment—Doxorubicin—uterine cancer	0.000155	0.000578	CcSEcCtD
Meloxicam—Alopecia—Epirubicin—uterine cancer	0.000154	0.000572	CcSEcCtD
Meloxicam—Mental disorder—Epirubicin—uterine cancer	0.000153	0.000567	CcSEcCtD
Meloxicam—Erythema multiforme—Doxorubicin—uterine cancer	0.000152	0.000567	CcSEcCtD
Meloxicam—Erythema—Epirubicin—uterine cancer	0.000152	0.000564	CcSEcCtD
Meloxicam—Malnutrition—Epirubicin—uterine cancer	0.000152	0.000564	CcSEcCtD
Meloxicam—Diarrhoea—Etoposide—uterine cancer	0.000151	0.000562	CcSEcCtD
Meloxicam—Eye disorder—Doxorubicin—uterine cancer	0.000151	0.00056	CcSEcCtD
Meloxicam—Tinnitus—Doxorubicin—uterine cancer	0.00015	0.000559	CcSEcCtD
Meloxicam—Cardiac disorder—Doxorubicin—uterine cancer	0.000149	0.000556	CcSEcCtD
Meloxicam—Flushing—Doxorubicin—uterine cancer	0.000149	0.000556	CcSEcCtD
Meloxicam—Flatulence—Epirubicin—uterine cancer	0.000149	0.000556	CcSEcCtD
Meloxicam—Tension—Epirubicin—uterine cancer	0.000149	0.000553	CcSEcCtD
Meloxicam—Dysgeusia—Epirubicin—uterine cancer	0.000148	0.000552	CcSEcCtD
Meloxicam—Nervousness—Epirubicin—uterine cancer	0.000147	0.000548	CcSEcCtD
Meloxicam—Back pain—Epirubicin—uterine cancer	0.000147	0.000545	CcSEcCtD
Meloxicam—Angiopathy—Doxorubicin—uterine cancer	0.000146	0.000544	CcSEcCtD
Meloxicam—Dizziness—Etoposide—uterine cancer	0.000146	0.000543	CcSEcCtD
Meloxicam—Muscle spasms—Epirubicin—uterine cancer	0.000146	0.000542	CcSEcCtD
Meloxicam—Immune system disorder—Doxorubicin—uterine cancer	0.000145	0.000541	CcSEcCtD
Meloxicam—Mediastinal disorder—Doxorubicin—uterine cancer	0.000145	0.00054	CcSEcCtD
Meloxicam—Arrhythmia—Doxorubicin—uterine cancer	0.000144	0.000535	CcSEcCtD
Meloxicam—Vision blurred—Epirubicin—uterine cancer	0.000143	0.000531	CcSEcCtD
Meloxicam—Alopecia—Doxorubicin—uterine cancer	0.000142	0.00053	CcSEcCtD
Meloxicam—Mental disorder—Doxorubicin—uterine cancer	0.000141	0.000525	CcSEcCtD
Meloxicam—Ill-defined disorder—Epirubicin—uterine cancer	0.000141	0.000523	CcSEcCtD
Meloxicam—Vomiting—Etoposide—uterine cancer	0.00014	0.000522	CcSEcCtD
Meloxicam—Malnutrition—Doxorubicin—uterine cancer	0.00014	0.000522	CcSEcCtD
Meloxicam—Erythema—Doxorubicin—uterine cancer	0.00014	0.000522	CcSEcCtD
Meloxicam—Anaemia—Epirubicin—uterine cancer	0.00014	0.000521	CcSEcCtD
Meloxicam—Rash—Etoposide—uterine cancer	0.000139	0.000518	CcSEcCtD
Meloxicam—Dermatitis—Etoposide—uterine cancer	0.000139	0.000517	CcSEcCtD
Meloxicam—Headache—Etoposide—uterine cancer	0.000138	0.000514	CcSEcCtD
Meloxicam—Flatulence—Doxorubicin—uterine cancer	0.000138	0.000514	CcSEcCtD
Meloxicam—Tension—Doxorubicin—uterine cancer	0.000138	0.000512	CcSEcCtD
Meloxicam—Dysgeusia—Doxorubicin—uterine cancer	0.000137	0.000511	CcSEcCtD
Meloxicam—Malaise—Epirubicin—uterine cancer	0.000137	0.000509	CcSEcCtD
Meloxicam—Nervousness—Doxorubicin—uterine cancer	0.000136	0.000507	CcSEcCtD
Meloxicam—Vertigo—Epirubicin—uterine cancer	0.000136	0.000507	CcSEcCtD
Meloxicam—Syncope—Epirubicin—uterine cancer	0.000136	0.000506	CcSEcCtD
Meloxicam—Leukopenia—Epirubicin—uterine cancer	0.000136	0.000505	CcSEcCtD
Meloxicam—Back pain—Doxorubicin—uterine cancer	0.000136	0.000505	CcSEcCtD
Meloxicam—Muscle spasms—Doxorubicin—uterine cancer	0.000135	0.000502	CcSEcCtD
Meloxicam—Palpitations—Epirubicin—uterine cancer	0.000134	0.000498	CcSEcCtD
Meloxicam—Loss of consciousness—Epirubicin—uterine cancer	0.000133	0.000496	CcSEcCtD
Meloxicam—Cough—Epirubicin—uterine cancer	0.000132	0.000492	CcSEcCtD
Meloxicam—Vision blurred—Doxorubicin—uterine cancer	0.000132	0.000492	CcSEcCtD
Meloxicam—Convulsion—Epirubicin—uterine cancer	0.000131	0.000489	CcSEcCtD
Meloxicam—Nausea—Etoposide—uterine cancer	0.000131	0.000488	CcSEcCtD
Meloxicam—Hypertension—Epirubicin—uterine cancer	0.000131	0.000487	CcSEcCtD
Meloxicam—Ill-defined disorder—Doxorubicin—uterine cancer	0.00013	0.000484	CcSEcCtD
Meloxicam—Anaemia—Doxorubicin—uterine cancer	0.00013	0.000482	CcSEcCtD
Meloxicam—Arthralgia—Epirubicin—uterine cancer	0.000129	0.00048	CcSEcCtD
Meloxicam—Myalgia—Epirubicin—uterine cancer	0.000129	0.00048	CcSEcCtD
Meloxicam—Anxiety—Epirubicin—uterine cancer	0.000129	0.000478	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000128	0.000477	CcSEcCtD
Meloxicam—Discomfort—Epirubicin—uterine cancer	0.000127	0.000474	CcSEcCtD
Meloxicam—Malaise—Doxorubicin—uterine cancer	0.000126	0.000471	CcSEcCtD
Meloxicam—Dry mouth—Epirubicin—uterine cancer	0.000126	0.00047	CcSEcCtD
Meloxicam—Vertigo—Doxorubicin—uterine cancer	0.000126	0.000469	CcSEcCtD
Meloxicam—Syncope—Doxorubicin—uterine cancer	0.000126	0.000468	CcSEcCtD
Meloxicam—Leukopenia—Doxorubicin—uterine cancer	0.000126	0.000467	CcSEcCtD
Meloxicam—Confusional state—Epirubicin—uterine cancer	0.000125	0.000464	CcSEcCtD
Meloxicam—Palpitations—Doxorubicin—uterine cancer	0.000124	0.000461	CcSEcCtD
Meloxicam—Oedema—Epirubicin—uterine cancer	0.000124	0.00046	CcSEcCtD
Meloxicam—Anaphylactic shock—Epirubicin—uterine cancer	0.000124	0.00046	CcSEcCtD
Meloxicam—Loss of consciousness—Doxorubicin—uterine cancer	0.000123	0.000459	CcSEcCtD
Meloxicam—Infection—Epirubicin—uterine cancer	0.000123	0.000457	CcSEcCtD
Meloxicam—Cough—Doxorubicin—uterine cancer	0.000122	0.000455	CcSEcCtD
Meloxicam—Shock—Epirubicin—uterine cancer	0.000122	0.000453	CcSEcCtD
Meloxicam—Convulsion—Doxorubicin—uterine cancer	0.000121	0.000452	CcSEcCtD
Meloxicam—Nervous system disorder—Epirubicin—uterine cancer	0.000121	0.000451	CcSEcCtD
Meloxicam—Thrombocytopenia—Epirubicin—uterine cancer	0.000121	0.000451	CcSEcCtD
Meloxicam—Hypertension—Doxorubicin—uterine cancer	0.000121	0.00045	CcSEcCtD
Meloxicam—Tachycardia—Epirubicin—uterine cancer	0.000121	0.000449	CcSEcCtD
Meloxicam—Skin disorder—Epirubicin—uterine cancer	0.00012	0.000447	CcSEcCtD
Meloxicam—Hyperhidrosis—Epirubicin—uterine cancer	0.00012	0.000445	CcSEcCtD
Meloxicam—Arthralgia—Doxorubicin—uterine cancer	0.000119	0.000444	CcSEcCtD
Meloxicam—Myalgia—Doxorubicin—uterine cancer	0.000119	0.000444	CcSEcCtD
Meloxicam—Anxiety—Doxorubicin—uterine cancer	0.000119	0.000443	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000119	0.000441	CcSEcCtD
Meloxicam—Discomfort—Doxorubicin—uterine cancer	0.000118	0.000439	CcSEcCtD
Meloxicam—Dry mouth—Doxorubicin—uterine cancer	0.000117	0.000434	CcSEcCtD
Meloxicam—Hypotension—Epirubicin—uterine cancer	0.000116	0.00043	CcSEcCtD
Meloxicam—Confusional state—Doxorubicin—uterine cancer	0.000115	0.000429	CcSEcCtD
Meloxicam—Anaphylactic shock—Doxorubicin—uterine cancer	0.000114	0.000426	CcSEcCtD
Meloxicam—Oedema—Doxorubicin—uterine cancer	0.000114	0.000426	CcSEcCtD
Meloxicam—Infection—Doxorubicin—uterine cancer	0.000114	0.000423	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000113	0.000419	CcSEcCtD
Meloxicam—Shock—Doxorubicin—uterine cancer	0.000113	0.000419	CcSEcCtD
Meloxicam—Nervous system disorder—Doxorubicin—uterine cancer	0.000112	0.000418	CcSEcCtD
Meloxicam—Thrombocytopenia—Doxorubicin—uterine cancer	0.000112	0.000417	CcSEcCtD
Meloxicam—Insomnia—Epirubicin—uterine cancer	0.000112	0.000416	CcSEcCtD
Meloxicam—Tachycardia—Doxorubicin—uterine cancer	0.000112	0.000416	CcSEcCtD
Meloxicam—Skin disorder—Doxorubicin—uterine cancer	0.000111	0.000414	CcSEcCtD
Meloxicam—Paraesthesia—Epirubicin—uterine cancer	0.000111	0.000413	CcSEcCtD
Meloxicam—Hyperhidrosis—Doxorubicin—uterine cancer	0.000111	0.000412	CcSEcCtD
Meloxicam—Dyspnoea—Epirubicin—uterine cancer	0.00011	0.00041	CcSEcCtD
Meloxicam—Somnolence—Epirubicin—uterine cancer	0.00011	0.000409	CcSEcCtD
Meloxicam—Dyspepsia—Epirubicin—uterine cancer	0.000109	0.000405	CcSEcCtD
Meloxicam—Decreased appetite—Epirubicin—uterine cancer	0.000108	0.0004	CcSEcCtD
Meloxicam—Hypotension—Doxorubicin—uterine cancer	0.000107	0.000398	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000107	0.000397	CcSEcCtD
Meloxicam—Fatigue—Epirubicin—uterine cancer	0.000107	0.000397	CcSEcCtD
Meloxicam—Pain—Epirubicin—uterine cancer	0.000106	0.000394	CcSEcCtD
Meloxicam—Constipation—Epirubicin—uterine cancer	0.000106	0.000394	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000104	0.000388	CcSEcCtD
Meloxicam—Insomnia—Doxorubicin—uterine cancer	0.000104	0.000385	CcSEcCtD
Meloxicam—Paraesthesia—Doxorubicin—uterine cancer	0.000103	0.000382	CcSEcCtD
Meloxicam—Dyspnoea—Doxorubicin—uterine cancer	0.000102	0.00038	CcSEcCtD
Meloxicam—Feeling abnormal—Epirubicin—uterine cancer	0.000102	0.000379	CcSEcCtD
Meloxicam—Somnolence—Doxorubicin—uterine cancer	0.000102	0.000379	CcSEcCtD
Meloxicam—Gastrointestinal pain—Epirubicin—uterine cancer	0.000101	0.000376	CcSEcCtD
Meloxicam—Dyspepsia—Doxorubicin—uterine cancer	0.000101	0.000375	CcSEcCtD
Meloxicam—Decreased appetite—Doxorubicin—uterine cancer	9.95e-05	0.00037	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Doxorubicin—uterine cancer	9.88e-05	0.000368	CcSEcCtD
Meloxicam—Fatigue—Doxorubicin—uterine cancer	9.87e-05	0.000367	CcSEcCtD
Meloxicam—Urticaria—Epirubicin—uterine cancer	9.83e-05	0.000366	CcSEcCtD
Meloxicam—Pain—Doxorubicin—uterine cancer	9.79e-05	0.000364	CcSEcCtD
Meloxicam—Constipation—Doxorubicin—uterine cancer	9.79e-05	0.000364	CcSEcCtD
Meloxicam—Body temperature increased—Epirubicin—uterine cancer	9.78e-05	0.000364	CcSEcCtD
Meloxicam—Abdominal pain—Epirubicin—uterine cancer	9.78e-05	0.000364	CcSEcCtD
Meloxicam—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	9.73e-05	0.00368	CbGpPWpGaD
Meloxicam—ABCC4—Ectoderm Differentiation—CCL2—uterine cancer	9.72e-05	0.00368	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	9.68e-05	0.00366	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.67e-05	0.00366	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—VEGFA—uterine cancer	9.66e-05	0.00365	CbGpPWpGaD
Meloxicam—Feeling abnormal—Doxorubicin—uterine cancer	9.43e-05	0.000351	CcSEcCtD
Meloxicam—Gastrointestinal pain—Doxorubicin—uterine cancer	9.36e-05	0.000348	CcSEcCtD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	9.35e-05	0.00354	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	9.2e-05	0.00348	CbGpPWpGaD
Meloxicam—PGD—Disease—AKR1C3—uterine cancer	9.13e-05	0.00345	CbGpPWpGaD
Meloxicam—Hypersensitivity—Epirubicin—uterine cancer	9.11e-05	0.000339	CcSEcCtD
Meloxicam—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	9.11e-05	0.00345	CbGpPWpGaD
Meloxicam—Urticaria—Doxorubicin—uterine cancer	9.09e-05	0.000338	CcSEcCtD
Meloxicam—Body temperature increased—Doxorubicin—uterine cancer	9.05e-05	0.000337	CcSEcCtD
Meloxicam—Abdominal pain—Doxorubicin—uterine cancer	9.05e-05	0.000337	CcSEcCtD
Meloxicam—PGD—Disease—HMGA1—uterine cancer	8.89e-05	0.00336	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	8.88e-05	0.00336	CbGpPWpGaD
Meloxicam—Asthenia—Epirubicin—uterine cancer	8.87e-05	0.00033	CcSEcCtD
Meloxicam—PGD—Metabolism—RRM2—uterine cancer	8.85e-05	0.00335	CbGpPWpGaD
Meloxicam—Pruritus—Epirubicin—uterine cancer	8.75e-05	0.000326	CcSEcCtD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	8.66e-05	0.00328	CbGpPWpGaD
Meloxicam—PGD—Metabolism—DCN—uterine cancer	8.59e-05	0.00325	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	8.57e-05	0.00324	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	8.52e-05	0.00322	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	8.52e-05	0.00322	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	8.47e-05	0.0032	CbGpPWpGaD
Meloxicam—Diarrhoea—Epirubicin—uterine cancer	8.46e-05	0.000315	CcSEcCtD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	8.46e-05	0.0032	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	8.44e-05	0.00319	CbGpPWpGaD
Meloxicam—Hypersensitivity—Doxorubicin—uterine cancer	8.43e-05	0.000314	CcSEcCtD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	8.41e-05	0.00318	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	8.31e-05	0.00314	CbGpPWpGaD
Meloxicam—Asthenia—Doxorubicin—uterine cancer	8.21e-05	0.000306	CcSEcCtD
Meloxicam—Dizziness—Epirubicin—uterine cancer	8.18e-05	0.000304	CcSEcCtD
Meloxicam—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	8.16e-05	0.00309	CbGpPWpGaD
Meloxicam—PGD—Disease—FBXW7—uterine cancer	8.13e-05	0.00308	CbGpPWpGaD
Meloxicam—Pruritus—Doxorubicin—uterine cancer	8.1e-05	0.000301	CcSEcCtD
Meloxicam—PGD—Metabolism—CYP11A1—uterine cancer	8.09e-05	0.00306	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	7.99e-05	0.00302	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	7.91e-05	0.00299	CbGpPWpGaD
Meloxicam—Vomiting—Epirubicin—uterine cancer	7.86e-05	0.000293	CcSEcCtD
Meloxicam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	7.86e-05	0.00297	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	7.85e-05	0.00297	CbGpPWpGaD
Meloxicam—Diarrhoea—Doxorubicin—uterine cancer	7.83e-05	0.000291	CcSEcCtD
Meloxicam—Rash—Epirubicin—uterine cancer	7.8e-05	0.00029	CcSEcCtD
Meloxicam—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	7.79e-05	0.00295	CbGpPWpGaD
Meloxicam—Dermatitis—Epirubicin—uterine cancer	7.79e-05	0.00029	CcSEcCtD
Meloxicam—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	7.76e-05	0.00294	CbGpPWpGaD
Meloxicam—Headache—Epirubicin—uterine cancer	7.75e-05	0.000288	CcSEcCtD
Meloxicam—PGD—Metabolism—AKR1C3—uterine cancer	7.64e-05	0.00289	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.61e-05	0.00288	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	7.59e-05	0.00287	CbGpPWpGaD
Meloxicam—Dizziness—Doxorubicin—uterine cancer	7.57e-05	0.000282	CcSEcCtD
Meloxicam—ABCC4—Hemostasis—IRF1—uterine cancer	7.47e-05	0.00282	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	7.41e-05	0.0028	CbGpPWpGaD
Meloxicam—Nausea—Epirubicin—uterine cancer	7.35e-05	0.000273	CcSEcCtD
Meloxicam—Vomiting—Doxorubicin—uterine cancer	7.28e-05	0.000271	CcSEcCtD
Meloxicam—Rash—Doxorubicin—uterine cancer	7.22e-05	0.000268	CcSEcCtD
Meloxicam—Dermatitis—Doxorubicin—uterine cancer	7.21e-05	0.000268	CcSEcCtD
Meloxicam—Headache—Doxorubicin—uterine cancer	7.17e-05	0.000267	CcSEcCtD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	7.15e-05	0.0027	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	7.13e-05	0.0027	CbGpPWpGaD
Meloxicam—ABCC4—Ectoderm Differentiation—CTNNB1—uterine cancer	7.09e-05	0.00268	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	7.05e-05	0.00267	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	6.98e-05	0.00264	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	6.88e-05	0.0026	CbGpPWpGaD
Meloxicam—Nausea—Doxorubicin—uterine cancer	6.8e-05	0.000253	CcSEcCtD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.76e-05	0.00256	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.76e-05	0.00256	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	6.5e-05	0.00246	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	6.39e-05	0.00242	CbGpPWpGaD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	6.37e-05	0.00241	CbGpPWpGaD
Meloxicam—PGD—Disease—CDKN2B—uterine cancer	6.37e-05	0.00241	CbGpPWpGaD
Meloxicam—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	6.31e-05	0.00239	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.25e-05	0.00237	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	6.25e-05	0.00236	CbGpPWpGaD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	6.22e-05	0.00235	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	6.19e-05	0.00234	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	6.16e-05	0.00233	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	6.08e-05	0.0023	CbGpPWpGaD
Meloxicam—PGD—Metabolism—STK11—uterine cancer	5.95e-05	0.00225	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CYP19A1—uterine cancer	5.95e-05	0.00225	CbGpPWpGaD
Meloxicam—PGD—Disease—SMAD3—uterine cancer	5.82e-05	0.0022	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	5.57e-05	0.00211	CbGpPWpGaD
Meloxicam—PGD—Disease—FGFR2—uterine cancer	5.55e-05	0.0021	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.5e-05	0.00208	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.5e-05	0.00208	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	5.48e-05	0.00207	CbGpPWpGaD
Meloxicam—PGD—Disease—MTHFR—uterine cancer	5.34e-05	0.00202	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NDUFB11—uterine cancer	5.25e-05	0.00199	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—SRD5A2—uterine cancer	5.25e-05	0.00199	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	5.13e-05	0.00194	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	5.13e-05	0.00194	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	5.1e-05	0.00193	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	5.06e-05	0.00192	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.96e-05	0.00188	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	4.89e-05	0.00185	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	4.87e-05	0.00184	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.81e-05	0.00182	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	4.76e-05	0.0018	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	4.76e-05	0.0018	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	4.6e-05	0.00174	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	4.54e-05	0.00172	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.48e-05	0.00169	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.48e-05	0.00169	CbGpPWpGaD
Meloxicam—PGD—Metabolism—MTHFR—uterine cancer	4.47e-05	0.00169	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	4.42e-05	0.00167	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	4.29e-05	0.00162	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	4.28e-05	0.00162	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—SRD5A2—uterine cancer	4.17e-05	0.00158	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NDUFB11—uterine cancer	4.17e-05	0.00158	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.05e-05	0.00153	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.04e-05	0.00153	CbGpPWpGaD
Meloxicam—PTGS2—Disease—AKR1B10—uterine cancer	3.87e-05	0.00146	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.82e-05	0.00145	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—STAR—uterine cancer	3.79e-05	0.00144	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—AKR1B1—uterine cancer	3.79e-05	0.00144	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	3.75e-05	0.00142	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.75e-05	0.00142	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.5e-05	0.00132	CbGpPWpGaD
Meloxicam—PGD—Disease—ERBB2—uterine cancer	3.49e-05	0.00132	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NDUFB11—uterine cancer	3.39e-05	0.00128	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—SRD5A2—uterine cancer	3.39e-05	0.00128	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	3.39e-05	0.00128	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	3.35e-05	0.00127	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	3.34e-05	0.00126	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.29e-05	0.00125	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.29e-05	0.00124	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.24e-05	0.00122	CbGpPWpGaD
Meloxicam—PGD—Disease—CDKN1B—uterine cancer	3.23e-05	0.00122	CbGpPWpGaD
Meloxicam—PTGS2—Disease—RNF43—uterine cancer	3.21e-05	0.00121	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.11e-05	0.00118	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.06e-05	0.00116	CbGpPWpGaD
Meloxicam—PGD—Disease—CTNNB1—uterine cancer	3.05e-05	0.00115	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—AKR1B1—uterine cancer	3.01e-05	0.00114	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—STAR—uterine cancer	3.01e-05	0.00114	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TP53—uterine cancer	2.99e-05	0.00113	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.98e-05	0.00113	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—POLD1—uterine cancer	2.98e-05	0.00113	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.98e-05	0.00113	CbGpPWpGaD
Meloxicam—PGD—Disease—PTEN—uterine cancer	2.97e-05	0.00112	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.84e-05	0.00108	CbGpPWpGaD
Meloxicam—PGD—Disease—EP300—uterine cancer	2.83e-05	0.00107	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—AKR1C1—uterine cancer	2.78e-05	0.00105	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.76e-05	0.00104	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.76e-05	0.00104	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—AKT1—uterine cancer	2.73e-05	0.00103	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.69e-05	0.00102	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.68e-05	0.00101	CbGpPWpGaD
Meloxicam—PGD—Disease—NRAS—uterine cancer	2.65e-05	0.001	CbGpPWpGaD
Meloxicam—PTGS2—Disease—AKR1C1—uterine cancer	2.64e-05	0.000999	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.53e-05	0.000957	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PTEN—uterine cancer	2.49e-05	0.000942	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—RRM2—uterine cancer	2.48e-05	0.000939	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—STAR—uterine cancer	2.45e-05	0.000927	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—AKR1B1—uterine cancer	2.45e-05	0.000927	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.42e-05	0.000916	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—DCN—uterine cancer	2.41e-05	0.000912	CbGpPWpGaD
Meloxicam—PGD—Metabolism—EP300—uterine cancer	2.37e-05	0.000898	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—POLD1—uterine cancer	2.36e-05	0.000894	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—EP300—uterine cancer	2.33e-05	0.000882	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.29e-05	0.000866	CbGpPWpGaD
Meloxicam—PTGS2—Disease—DCN—uterine cancer	2.28e-05	0.000864	CbGpPWpGaD
Meloxicam—PGD—Disease—KRAS—uterine cancer	2.28e-05	0.000863	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP11A1—uterine cancer	2.27e-05	0.000859	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—AKR1C1—uterine cancer	2.21e-05	0.000836	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—VEGFA—uterine cancer	2.21e-05	0.000835	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—NRAS—uterine cancer	2.18e-05	0.000825	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—AKR1C3—uterine cancer	2.14e-05	0.000811	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.1e-05	0.000795	CbGpPWpGaD
Meloxicam—PGD—Disease—PIK3CA—uterine cancer	2.1e-05	0.000793	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.03e-05	0.00077	CbGpPWpGaD
Meloxicam—PTGS2—Disease—AKR1C3—uterine cancer	2.03e-05	0.000769	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—STAR—uterine cancer	1.99e-05	0.000755	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.99e-05	0.000755	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HMGA1—uterine cancer	1.98e-05	0.000749	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.97e-05	0.000746	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—RRM2—uterine cancer	1.97e-05	0.000745	CbGpPWpGaD
Meloxicam—PGD—Disease—HRAS—uterine cancer	1.94e-05	0.000734	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—POLD1—uterine cancer	1.92e-05	0.000728	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—DCN—uterine cancer	1.91e-05	0.000724	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—KRAS—uterine cancer	1.88e-05	0.00071	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.82e-05	0.000688	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.82e-05	0.000688	CbGpPWpGaD
Meloxicam—PTGS2—Disease—FBXW7—uterine cancer	1.81e-05	0.000685	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP11A1—uterine cancer	1.8e-05	0.000682	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.8e-05	0.000681	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PIK3CA—uterine cancer	1.76e-05	0.000664	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—PIK3CA—uterine cancer	1.72e-05	0.000652	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.72e-05	0.00065	CbGpPWpGaD
Meloxicam—PGD—Disease—AKT1—uterine cancer	1.71e-05	0.000648	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—AKR1C3—uterine cancer	1.7e-05	0.000644	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP19A1—uterine cancer	1.67e-05	0.000632	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—STK11—uterine cancer	1.67e-05	0.000632	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TP53—uterine cancer	1.67e-05	0.000631	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—RRM2—uterine cancer	1.6e-05	0.000607	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—HRAS—uterine cancer	1.6e-05	0.000604	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.57e-05	0.000593	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—POLD1—uterine cancer	1.57e-05	0.000592	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—DCN—uterine cancer	1.56e-05	0.000589	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.5e-05	0.000566	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.47e-05	0.000555	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.46e-05	0.000554	CbGpPWpGaD
Meloxicam—PGD—Metabolism—AKT1—uterine cancer	1.43e-05	0.000543	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CDKN2B—uterine cancer	1.42e-05	0.000537	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—AKT1—uterine cancer	1.41e-05	0.000533	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.38e-05	0.000524	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—STK11—uterine cancer	1.33e-05	0.000502	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP19A1—uterine cancer	1.33e-05	0.000502	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.32e-05	0.000498	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—STAR—uterine cancer	1.32e-05	0.000498	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—RRM2—uterine cancer	1.3e-05	0.000494	CbGpPWpGaD
Meloxicam—PTGS2—Disease—SMAD3—uterine cancer	1.3e-05	0.00049	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—DCN—uterine cancer	1.27e-05	0.000479	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—MTHFR—uterine cancer	1.26e-05	0.000475	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.24e-05	0.000471	CbGpPWpGaD
Meloxicam—PTGS2—Disease—FGFR2—uterine cancer	1.24e-05	0.000468	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.000451	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MTHFR—uterine cancer	1.19e-05	0.00045	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.19e-05	0.000449	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.13e-05	0.000426	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.11e-05	0.000418	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—STK11—uterine cancer	1.08e-05	0.000408	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.08e-05	0.000408	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—POLD1—uterine cancer	1.03e-05	0.000391	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.01e-05	0.000383	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—MTHFR—uterine cancer	9.96e-06	0.000377	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.66e-06	0.000365	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKR1C1—uterine cancer	9.65e-06	0.000365	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—STK11—uterine cancer	8.78e-06	0.000332	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP19A1—uterine cancer	8.78e-06	0.000332	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.78e-06	0.000332	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—RRM2—uterine cancer	8.61e-06	0.000326	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—DCN—uterine cancer	8.35e-06	0.000316	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.24e-06	0.000312	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—MTHFR—uterine cancer	8.11e-06	0.000307	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP11A1—uterine cancer	7.87e-06	0.000298	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.86e-06	0.000297	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERBB2—uterine cancer	7.76e-06	0.000294	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKR1C3—uterine cancer	7.43e-06	0.000281	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CDKN1B—uterine cancer	7.19e-06	0.000272	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.14e-06	0.00027	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTEN—uterine cancer	6.98e-06	0.000264	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CTNNB1—uterine cancer	6.79e-06	0.000257	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—EP300—uterine cancer	6.66e-06	0.000252	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PTEN—uterine cancer	6.62e-06	0.00025	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—MTHFR—uterine cancer	6.6e-06	0.00025	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EP300—uterine cancer	6.31e-06	0.000239	CbGpPWpGaD
Meloxicam—PTGS2—Disease—NRAS—uterine cancer	5.9e-06	0.000223	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.81e-06	0.00022	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP19A1—uterine cancer	5.79e-06	0.000219	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—STK11—uterine cancer	5.79e-06	0.000219	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PTEN—uterine cancer	5.54e-06	0.00021	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—EP300—uterine cancer	5.29e-06	0.0002	CbGpPWpGaD
Meloxicam—PTGS2—Disease—KRAS—uterine cancer	5.08e-06	0.000192	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PIK3CA—uterine cancer	4.93e-06	0.000186	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PIK3CA—uterine cancer	4.67e-06	0.000177	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTEN—uterine cancer	4.51e-06	0.000171	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—MTHFR—uterine cancer	4.35e-06	0.000165	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HRAS—uterine cancer	4.32e-06	0.000163	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—EP300—uterine cancer	4.3e-06	0.000163	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—AKT1—uterine cancer	4.02e-06	0.000152	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PIK3CA—uterine cancer	3.91e-06	0.000148	CbGpPWpGaD
Meloxicam—PTGS2—Disease—AKT1—uterine cancer	3.81e-06	0.000144	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTEN—uterine cancer	3.67e-06	0.000139	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—EP300—uterine cancer	3.5e-06	0.000132	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—AKT1—uterine cancer	3.19e-06	0.000121	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.18e-06	0.00012	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—AKT1—uterine cancer	2.6e-06	9.83e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.59e-06	9.8e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTEN—uterine cancer	2.42e-06	9.16e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—EP300—uterine cancer	2.31e-06	8.73e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—AKT1—uterine cancer	2.12e-06	8e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.71e-06	6.46e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—AKT1—uterine cancer	1.4e-06	5.28e-05	CbGpPWpGaD
